Standard dose EC-Mycophenolate Sodium (MPS) delivers rapid therapeutic mycophenolic acid exposure in kidney transplant recipients.
EC-Mycophenolate Sodium (MPS) is a salt that combines an acid-MPA with a base-sodium. The enteric coating delays MPS's release so that the EC-MPS is absorbed in the small intestine [1-12].
Mycophenolic acid is an uncompetitive, reversible inhibitor of inosine monophosphate dehydrogenase (IMPDH). Mycophenolic acid inhibits IMPDH, needed for the functioning of the de novo pathway of guanosine (purine) nucleotide synthesis and crucial for lymphocyte proliferation . Thus, MPA mostly effects activated lymphocytes rather than inactive lymphocytes. The apparently low hepatotoxicity, nephrotoxicity, and carcinogenicity of MMF have made it a useful therapeutic agent.